Loading patent…
AssigneesInstitut Curie, Mnemo Therapeutics, Institut National De La Sante Et De La Recherche Medical (Inserm)
InventorsSebastian AMIGORENA, Marianne BURBAGE, Alexandre HOUY, Marc-Henri STERN, Joshua WATERFALL, Benjamin SADACCA, Antonela MERLOTTI IPPOLITO, Yago ARRIBAS DE SANDOVAL
Estimating the term…
The present disclosure relates to a method for selecting a tumor neoantigenic peptide wherein said method comprises: a step of identifying, among mRNA sequences from cancer cells of a subject, a fusion transcript sequence comprising a transposable element (TE) sequence and an exonic sequence, and including an open reading frame (ORF), and a step of selecting a tumor neoantigenic peptide of at least 8 amino acids, encoded by a part of said ORF of the fusion transcript sequence, wherein said ORF overlaps the junction between the TE and the exonic sequence, is pure TE and/or is non-canonical, and wherein said tumor neoantigenic peptide binds to at least one Major Histocompatibility Complex (MHC) molecule of said subject. The present disclosure also relates to tumor neoantigenic peptide obtained according to the present method, vaccine or immunogenic composition, antibodies and immune cells derived thereof and their use in therapy of cancer.
1-24. (canceled)
A method of antibody production, comprising a step of contacting multiple antibodies or antigen-binding fragments thereof with a tumor neoantigen peptide and selecting an antibody, or antigen-binding fragment thereof, that binds to
28-35. (canceled)
42-44. (canceled)
Dependencies are inferred from the claim text.